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Abstract: Polysaccharides, such as cellulose, hyaluronic acid, alginic acid, and chitosan, as well as
polysaccharide derivatives, have been successfully used to augment drug delivery in the treatment of
ocular pathologies. The properties of polysaccharides can be extensively modified to optimize ocular
drug formulations and to obtain biocompatible and biodegradable drugs with improved bioavailability
and tailored pharmacological effects. This review discusses the available polysaccharide choices
for overcoming the difficulties associated with ocular drug delivery, and it explores the reasons for
the dependence between the physicochemical properties of polysaccharide-based drug carriers and
their efficiency in different formulations and applications. Polysaccharides will continue to be of
great interest to researchers endeavoring to develop ophthalmic drugs with improved effectiveness
and safety.
Keywords: eye tissue regeneration; intravitreal administration; ocular bioavailability; ocular drug
delivery; periocular administration; polysaccharide; topical administration
1. Introduction
Drug efficacy and safety are essential prerequisites for any pharmaceutical product. However,
the desired efficacy and safety conditions are often difficult to achieve in ophthalmological settings
due to limitations in drug delivery associated with the route of drug administration and imposed by
the barriers related to the anatomy and physiology of the eye. For this reason, polymeric carriers and
excipients are now being used to enhance ocular drug delivery, and several reviews have described the
use of synthetic and natural polymers for this purpose. For example, Formica et al. [1] reviewed the
properties of natural polymers and the use of natural polymers for the preparation of nanocarriers for
topical ocular drug administration. Similarly, Nayak et al. [2] discussed the properties of liposomes,
emulsions, nano- and microspheres, and conjugates as ophthalmic drug formulations, although
the topical and intravitreal systems used in that study were based on non-natural biodegradable
polymers, such as poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and polyvinyl
alcohol. Tsai et al. [3] examined the use of the polysaccharide chitosan in eye drops for DNA delivery
to the eye, but no reviews have yet explored the effectiveness of drug delivery to various eye segments
in terms of the properties of polysaccharides and their derivatives, nor have ophthalmic drug delivery
systems based on polysaccharides been described in detail. The aim of this review was therefore to
summarize the current advances being made in the development of ocular drug carriers based on
Pharmaceutics 2020, 12, 22; doi:10.3390/pharmaceutics12010022 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2020, 12, 22 2 of 30
natural and semi-synthetic polysaccharides, with emphasis on the properties of polysaccharides as
drug carriers and their biological interactions in the eye.
The human eye has a complex anatomical and physiological structure that includes both mechanical
and chemical barriers that complicate drug delivery to the eye (Figure 1A). Three main routes are
available for local ocular drug delivery: topical, periocular (subconjunctival, sub-tenon, peribulbar etc.),
and intravitreal (Figure 1B). Some rarely used additional routes of local ocular drug delivery (including
subretinal and suprachoroidal) are also available (Figure 1B). The drug bioavailability depends on the
route of drug administration into the eye. Therefore, the anatomical and physiological features of the
eye must be taken into account when designing drug delivery systems.
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Ocular drugs can be administered systemically (as parenteral injections or by the oral route).
The main advantages of systemic over intraocular drug delivery include the convenience of drug
administration and greater ocular safety; h wever, the required drug doses, and therefore the risks of
systemic dverse effects, are increased [4]. The delivery of systemically administered drugs to the retina
is limited by various factors, including gastrointestinal barriers for the oral route, wi e distribution of
the drug to off-target sites, and the pr sence of the blood-retinal barrier [5]. These limitations mean
that systemically administered drugs have extremely l w ocular bioavailability and must therefore be
administ red as large daily rug doses [6,7]. This review will focus on the use of polysaccharides as
vehicles that can facilitate locally administered drug delivery.
2. Polysaccharides Used in Ophthalmology
Natural polysaccharides are attractive options for the formulation of ocular medications, as these
polysaccharides are economical, readily available, non-toxic, potentially biodegradable, generally
biocompatible, and typically amenable to chemical modifications [8–13]. Indeed, chemical modifications
have recently led to derivatives with improved properties in terms of rheology, mucoadhesion, increased
ocular retention, and drug solubilization [14–18].
Currently, the Food and Drug Administration (FDA) allows clinical ophthalmic use of the
polysaccharides listed in Table 1. Most of these are presently added to commercially available eye
drops as inert thickening agents, although some are used for eye surgery (e.g., hyaluronic acid) or
as intravitreal implants (e.g., microcrystalline cellulose). In the coming years, this list will probably
expand [19,20].
Cellulose derivatives were the first group of polymers to be used as components in topical
ophthalmic dosage forms, and cellulose-based materials remain the most widely used polymers
in ophthalmology [21]. Pure cellulose is not water soluble due to its relatively high crystallinity,
so cellulosic derivatives were first used as viscolizers in eye drops. These derivatives included
methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose
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(HPMC), and carboxymethyl cellulose (CMC). The main disadvantage of these derivatives is that
defining a boundary between viscous solutions and an undesired gel phase is challenging because
data on polymer concentrations or the formulation viscosities are not always available. Nevertheless,
many cellulosic polymers are currently components of ocular products (Table 1).
Table 1. List of FDA-approved polysaccharides used as excipients for ophthalmological drugs [22].
Polysaccharide Administration 1
Drug Dosage
Form Max Potency
2 Brand Names
Alginate sodium T insert 1 mg -
Carboxymethyl
cellulose sodium IVT, T
suspension,
injection, solution 0.5% Refresh Tears
Guar gum T suspension 0.2% -
Hyaluronate
sodium IVT injectable solution 2.3%
Healon, Amvisc,
Provisc, AMO
Vitrax
Hydroxyethyl
cellulose T
solution,
suspension 0.25–1.6% Rohto Hydra
Hydroxyethyl
ethylcellulose T solution 0.48% -
Hyproxypropyl
methylcellulose T
solution,
suspension, gel
0.1–0.6%; 2.25%
(gel)
Genteal, Nature’s
Tears, Tearisol
Methylcellulose T solution,suspension 0.05–0.5% Murocel
Microcrystalline
cellulose IVT implant 1.66 mg Retisert
Xanthan gum T solution,suspension 0.6% I-Dew Ultra
1 T—topical ophthalmic, IVT—intravitreal; 2 maximum potency is the amount of the excipient used in the approved
product that is the basis for the IID listing. The potency is given in mg for ocular inserts and in percentage for
liquid formulations.
The types of polysaccharides used in these products have recently been extended to include
other compounds, such as chitosan and its derivatives, hyaluronic acid (HA), and alginic acid (ALG).
These are sometimes preferred over cellulosic derivatives for certain applications.
HA is a natural polysaccharide found in the skin, connective tissues, umbilical cord, and the
vitreous body of the eye. The main advantages of HA include its excellent biocompatibility and
mucoadhesiveness, as well as its pseudoplastic and viscoelastic behavior. Its use as a vehicle in ocular
drug delivery has been reviewed previously [23,24].
HA is used as the vehicle in tear substitutes, since it has protective effects against damage caused
by benzalkonium chloride, a commonly used preservative in eye drops [25]. The extended residence
of HA on the ocular surface is one of its advantages for use as an artificial tear component in dry eye
therapy. Pseudoplastic behavior is another advantage provided by HA eye drops, as this property
ensures good spreading of the polymer on the ocular surface upon blinking. HA can also be cross-linked
and formulated as films, inserts, or particles to prolong drug release, precorneal residence, and/or
drug action (e.g., the ocular hypotensive effects of timolol) [26]. Some commercial HA-containing
products are also available as surgical aids for anterior segment procedures (e.g., cataract extraction
and intraocular lens implantation).
Chitosan is another emerging polymer being considered for ophthalmic use [27,28]. Mucoadhesive
chitosan formulations have been investigated as a strategy to overcome the rapid elimination of instilled
ophthalmic solutions. Overall, chitosan-based formulations appear less viscous than those based on
traditional viscolizers like HA. Another possible advantage of chitosan is the presence of positive
charges on its backbone at physiological pH. These positive charges are thought to interact with
the negative charges of the ocular mucus, thereby enhancing bioadhesion. Chitosan formulations
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have shown promising results due to their significantly longer retention on the corneal surface when
compared with conventional commercial ophthalmic solutions [27,29,30].
ALG is a seaweed-derived polysaccharide composed of β-d-mannuronate (M) and α-l-guluronate
residues (G). Solutions of ALG can be crosslinked to form a hydrogel by a mild gelling reaction
that involves exposure to divalent or trivalent cations [31]. Most commonly, gelation is achieved
using Ca2+ ions, usually by immersion of the ALG in a bath of CaCl2 to elicit the mild gelling
reaction. The Ca2+-induced crosslinks are known to dissipate from the scaffold over time in response to
exposure of the scaffold to other ions (e.g., Na+, K+, Mg2+, or phosphates), and this results in scaffold
degradation [32]. The mechanical properties of ALG gels can be tailored by altering various features,
including the molecular weight (MW) of the polymer, the G:M ratio, the cross-linking species, and the
concentration of cross-linking cations [33,34].
Pectin is a natural polymer constituent of many plant cell walls, and it is extensively employed in
the food industry and biomedicine. It is a branched macromolecule with a high MW, so pectin can be
converted into swellable hydrogels, particularly from solutions with high pectin concentrations and at
low pH conditions, as these conditions facilitate the formation of the coil entanglements responsible
for gel formation. Water-insoluble gels can also be obtained by cross-linking with divalent or trivalent
cations. Depending on the degree of esterification, pectins are classified as low methoxyl (<50%) or
high methoxyl (>50%) forms that have dissimilar gelling properties [35]. The use of pectin hydrogels
has been evaluated as a strategy for enhancing drug contact time and ocular absorption. An alternative
approach is to apply pectin for in-situ gel formation. In the eye, pectin applied in a liquid form will
spontaneously form a gel in response to the neutral lacrimal pH and the presence of the lacrimal
electrolytes [36].
Other polysaccharides have also been evaluated as potential vehicles for prolonging the residence
time of drugs at the surface of the eye. Xanthan gum is one example of a negatively charged polymer
that has been proposed as a material for artificial tear preparations [37], and as a vehicle for drug
delivery [38]. For example, Saettone et al. [39] evaluated the transcorneal delivery of pilocarpine from
several ophthalmic formulations and demonstrated that 1.5% xanthan gum significantly improved
both pilocarpine bioavailability and the duration of the drug action.
3. Topical Administration
3.1. Barriers to Topical Delivery of Ocular Drugs
Topical instillation is the most common ocular drug delivery method, particularly for outpatient
treatments. However, drug bioavailability to the anterior eye segment (cornea, aqueous humor, iris,
and ciliary body) is generally less than 5%, and it is 2–3 orders of magnitude lower still in the posterior
segment, which contains the retina. The inability to deliver drugs by topical and systemic routes and/or
the inefficiency of those routes for retinal delivery of existing drugs is now widely accepted [40]. The low
levels of drug absorption are due to the presence of anatomical and physiological barriers that include
nasolacrimal drainage, the corneal barrier, and non-target absorption of drugs by the conjunctiva [41].
Ocular absorption can be increased by prolonging the residence time of the formulation on the ocular
surface using ointments or polymeric inserts but increased ocular contact time with ointments has led
to blurred vision and polymeric inserts are often ineffective due to a lack of patient compliance. Thus,
new systems are needed that will provide prolonged drug action and better patient compliance.
Drug bioavailability from eye drops is hampered by ocular barriers that limit drug exposure to
the ocular surface and prevent permeation into the target region of the eye [42]. The cornea is the
main route of drug absorption into the ocular tissues [43], but the permeability of the cornea to a drug
instilled as an eye drop depends on the drug properties, such as its lipophilicity, hydrogen bonding
capability, and molecular size [44,45]. The physical features of the formulation itself can also affect drug
availability. For example, exposure of the eye to a hypotonic ophthalmic solution causes an increase in
the permeability of the corneal epithelium, with a possible triggering of edema. Conversely, exposure
Pharmaceutics 2020, 12, 22 5 of 30
to a hypertonic solution has a dehydrating effect. However, in practice, this response is not necessarily
strict, as many eye drops are hypertonic and the eye can withstand hypotonic solutions [46].
Control of the formulation pH is also important for drug absorption, since corneal permeation is
higher for non-ionized forms of drugs than for ionized forms [47]. In addition, pH is often important
for stability of the drug in the formulation. Many formulations have an acidic pH range (3.5–6.3),
so they can cause an initial, but usually acceptable, discomfort upon application (the normal lacrimal
pH is 7.4) [48]. Similarly, the administration of solutions that have a surface tension lower than that
of the tears may destabilize the lacrimal lipid film and disperse it as lipid droplets. The integrity of
the oily film formed by the lacrimal fluid is essential because it reduces the rate of evaporation of the
water layer, thereby improving the retention of water in the tear film and preventing dry eye [49].
3.2. Eye Drops and Artificial Tears
Viscosifying agents are used in ophthalmic solutions to prolong the retention time of the drug
on the surface of the eye. In general, a higher viscosity leads to higher precorneal retention times.
On occasion, viscous solutions are poorly tolerated by patients because of shearing forces that
occur during eye movements and blinking. Therefore, pseudoplastic (shear-thinning) properties
are advantageous in formulations intended for topical administration [50]. In addition to increased
viscosity, factors like mucoadhesion and comfort upon instillation play further significant roles [51].
Several polymers, including chitosan, HA, ALG, cellulose derivatives, arabinogalactan, xyloglucan,
gellan gum, and their mixtures, have been proposed for eye drops and for in-situ gelling systems.
Among these polysaccharides, chitosan shows the best mucoadhesion because of its cationic nature.
Different polysaccharides, such as ALG, tamarind seed polysaccharides (TSP), HA, and hydroxyethyl
cellulose, have been compared for their ability to resist removal from tear fluid. Their mucoadhesivity
has been examined both in vitro (using the polymer-induced increase in the viscosity of a mucin
dispersion) and in vivo (using the polymer residence time in rabbit tear fluid) [52]. An optimal
excipient polymer in eye drops should be mucoadhesive but not excessively viscous when in solution.
A solution of TSP (0.7% w/v) had the highest mean precorneal retention time in the rabbit eye. By virtue
of its mucoadhesivity, TSP (0.7% w/v) also prolonged the residence of the drugs ketotifen fumarate
and diclofenac sodium in the precorneal area of rabbit eyes [52]. HA and hydroxyethyl cellulose
are also mucoadhesive, but their solutions are too highly viscous and could cause discomfort to the
patients by potentially inducing reflex tearing. At similar concentrations, ALG did not show significant
mucoadhesion, but it did not increase the solution viscosity, so it can be used at higher concentrations
(up to 5–10%) to provide mucoadhesion [52,53].
Polymer solutions are used for their interactions with the ocular surface, which prevent the
loss of cellular volume while suppressing cellular stress and inflammatory reactions. For example,
a combination of CMC and HA (a natural component of the tear film) improves the water retention
and viscoelasticity of the lacrimal film [54]. A double-blinded multicenter study of 305 subjects
demonstrated that an artificial tear formulation of a novel multi-ingredient formulation provided
the best improvement in ocular symptoms and ocular staining. This formulation contains 0.5%
CMC, 0.1% HA, salts, osmoprotectants (glycerin and erythritol), and a stabilized oxychloro complex
(for preservation) [55]. Treatment with a lubricant eye drop containing PEG, propylene glycol,
and hydroxypropyl guar preserved with polyquaternium-1 also reduced the severity of dry eye disease
(DED) and surface inflammation by reducing the number of cells with D-related human leukocyte
antigen on the ocular surface [56]. D-related human leukocyte antigen plays an important role in
T-cell activation and is overexpressed in many patients with DED [57]. Assessments conducted in that
study included DED severity, corneal and conjunctival staining, tear film breakup time, Schirmer tests,
and impression cytology of the conjunctiva with masked flow cytometry at baseline and 30 days.
Another tested artificial tear preparation contained two active ingredients: HA and trehalose [54].
In general, trehalose stabilizes lipid membranes and proteins against desiccation, and it does so in
the eye as well. These artificial tears were compared with a preparation containing hyperbranched
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polyglycerol and polyquaternium-1 preservative, and both formulations were found effective for the
treatment of DED in blinded multicenter studies with patients with dry eye symptoms. The effects on
tear breakup time and ocular surface damage have also been measured after delivery of formulations
containing CMC, glycerol, polysorbate, and emulsified lipid [55]. The lipid-containing artificial tears
could also be used to counteract the lipid deficiency associated with DED.
One study focused on maximizing the viscosity and mucoadhesiveness of HA-based
preparations [58] by examining the range of MWs encountered in commercial products.
The concentrations varied from 0.3 wt% for an 1100 kDa HA, up to 1.0 wt% for a 250 kDa HA
(i.e., three-fold higher than the highest concentration in the clinical products). The viscosity and
mucoadhesion profiles of the optimized formulations were superior to those of the commercial
products, especially under conditions that simulated in vivo blinking, and therefore predicted longer
retention on the corneal epithelium. An enhanced capacity to protect corneal porcine epithelial cells
from dehydration was also demonstrated in vitro. Overall, the results predicted formulations with
improved efficacy.
A dual-polymer formulation consisting of hydroxypropyl guar and HA was as effective as HA
lubricant eye drops for improving ocular surface staining in DED. The hydroxypropyl guar-HA
formulation did not improve the scores for everyday life treatment satisfaction in patients with DED
when compared to HA, but no new safety concerns were reported [59].
Excipients have also been used in eye drops to increase ocular bioavailability. These materials
include micelles [60], nanoparticles, mucoadhesives, in-situ-forming hydrogels, and contact lenses [61].
Note that the use of natural polymers, such as ALG, Veegum®, xanthan gum, gelatin, acacia gum,
and tragacanth gum, may carry a high risk of bacterial and fungal contamination [62].
3.3. Mucoadhesives
Mucoadhesion refers to the adhesion of an exogenous material to the mucin on an epithelial
surface, for example, in the eye. Mucoadhesion is explained by four main mechanisms: electrostatic,
adsorption, wetting, and diffusion [63]. In general, mucoadhesion is a combination of many processes.
First, the polymer swells, as described in the wetting theory, and then non-covalent (physical) bonds
are formed at the mucus-polymer interface (electrostatics and adsorption). Thereafter, the chains of the
polymer and mucin interpenetrate and entangle to form more bonds via the four mechanisms [63,64].
Many polysaccharides are mucoadhesive at comparatively low viscosities, making them suitable
for prolongation of eye drop contact time and for the treatment of DED. Mucoadhesion allows
the drops to stabilize the tear film and prolong the residence time of ophthalmic drugs on the eye
surface. Chitosan and some of its polycationic derivatives display mucoadhesion and promotion
of ocular drug absorption via reversible permeabilization of the cornea [27]. This process has
been utilized in further development of chitosan as component of nanoparticles and in-situ gelling
systems [65]. In contrast, Rodriguez et al. [66] have indicated that mucoadhesive polysaccharides
(chitosan, HA, and ALG) significantly reduce the permeability of the anti-glaucoma drug timolol
maleate through ex vivo bovine corneas. The addition of permeability enhancers (like ethylene
glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid or hydroxypropyl-β-cyclodextrin) led to a
further reduction in drug permeability when compared to the polymers alone. These results highlight
the need for the careful selection of additives intended for ocular applications, since interactions
between them can have opposite results to those expected in terms of drug permeability [66].
The use of polysaccharides, such as ALG or gellan gum, as the basic excipients of in-situ-gelling
systems revealed that the basic principles underlying any increase in drug bioavailability were the
prolonged retention of the gel in the precorneal area and the slow release of the drug from the gel.
Bravo-Osuna et al. [67] used surface plasmon resonance to study the mucoadhesive properties of
various polysaccharides toward ocular mucins. Chitosan, being a cationic polymer, was found to form
ionic bonds with anionic sialic acid and sulfonic acid groups, whereas the primary forces for retention
of anionic polysaccharides, such as CMC and HA, were hydrogen bonding and interpolymer diffusion.
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Eye drop formulations have been prepared using HPMC (0.75%, w/v) in an isotonic solution
incorporating chitosan/sodium tripolyphosphate-HA (chitosan/TPP-HA) nanoparticles loaded with
ceftazidime [29]. The viscosity of the nanoparticles and the gels incorporating the nanoparticles were
characterized after contact with mucin at different mass ratios to calculate the rheological synergism
parameter. Different ratios of the nanoparticle eye formulation to mucin weights gave a minimum
viscosity that resulted in a negative rheological synergism. The mucoadhesivity of this novel ocular
formulation and its ability to interact with the ocular surface were improved, thereby increasing
the drug residence time in the eye. In-vitro release and permeation studies showed a prolonged
drug release profile from the chitosan/TPP-HA nanoparticle gel formulation. Furthermore, the gel
formulation was not cytotoxic to ARPE-19 and HEK293T cell lines, as evaluated by metabolic and
membrane integrity tests. The formulation was stable, and the drug retained its activity, as shown by
microbiological studies. Thus, chitosan/TPP-HA nanoparticle eye drop formulations are a promising
platform for enhancing the mucoadhesive properties of ocularly delivered drugs.
Chitosan binds to mucin by electrostatic interactions (i.e., between the positively charged amino
groups of chitosan and the negatively charged sialic acid residues of mucin), by the formation of
hydrogen bonds, and by hydrophobic forces [64,68]. The mucoadhesive properties of chitosan depend
on the MW and viscosity of the polymer, as higher MW chitosan has a greater affinity for mucin.
High-mucoadhesion chitosan can contract the mucin gel network to create large pores throughout the
gel network. These pores then can promote the diffusion of chitosan-based micro and nanoparticles
through the mucus layer [69,70].
3.4. In-Situ-Forming Hydrogels
3.4.1. Features of In-Situ-Forming Hydrogels
Ocular in-situ-forming gels are a promising alternative to other drug delivery methods and may
overcome the drawbacks of conventional eye drops because they retain the advantages of solutions,
such as the ease of administration for outpatients and the prolonged contact time of ointments. However,
the use of preformed hydrogels has drawbacks that can limit their use in ophthalmic drug delivery or as
tear substitutes. For example, they do not allow accurate and reproducible administration of drug doses,
and they often produce blurred vision, crusting of eyelids, and lacrimation following administration.
In-situ-forming hydrogels are instilled as eye drops, but they immediately undergo gelation upon
contact with the lacrimal fluid. These hydrogels are therefore stimulus sensitive, and they differ in this
respect from inert hydrogels. They can “sense” changes in environmental properties, such as pH and
temperature, and then respond by increasing or decreasing their degree of swelling by adjustments in
the intricately entangled polymers strands. These formulations seem particular promising, especially
since new “patentable” entities might be obtained through in-depth studies of associations of already
well-established products. When supplied as eye drops, an in-situ sensing hydrogel are expected to
mix with tear fluid and alter its gelation in response to the physicochemical characteristics of the film,
which contains many ions and has an osmotic pressure equivalent to that of 0.9% saline, a temperature
of +32 ◦C, and a pH of 7.4. However, one disadvantage of this approach is that the volume of normal
tear fluid is only 7 µL, while eye drop volumes usually range from 30–40 µL. Therefore, the eye drop
properties may dominate over the lacrimal fluid, making the impact of lacrimal fluid on gel formation
inadequate or too slow.
Several in-situ-forming hydrogels have been tested for topical ocular administration.
Notably, chemical modification or graft copolymerization of polysaccharides provides almost
unlimited opportunities to combine biodegradability, low toxicity, and mucoadhesivity of different
polymers with the functional properties of synthetic polymers. For example, a copolymer of
poly(N-isopropylacrylamide) (PNIPAAm) with chitosan was used to produce thermosensitive eye drops
for topical administration of timolol. The mucoadhesive features of chitosan, along with the gelation of
the copolymer at a low critical solution temperature (32 ◦C) due to the PNIPAAm components, resulted
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in improved pharmacokinetics compared to commercially available eye drops [71]. The PNIPAAm-HA
copolymer demonstrated excellent biocompatibility with retinal pigment epithelial (RPE) cells and
elicited only a minor inflammatory response, making this formulation potentially suitable for ocular
drug delivery even in the form of intraocular injections [72].
3.4.2. In-Situ-Forming Gels Influenced by Ionic Strength
Ionic-strength-responsive polymers undergo their phase transitions in response to changes
in the surrounding salt concentrations (e.g., ionic strength). One example of an ion-responsive
material is gellan gum, an anionic polysaccharide produced by the bacterium Pseudomonas elodea [73].
After dispersion in aqueous solutions, gellan gum undergoes a liquid-gel transition in response to
increases in ionic strength [74]. This sol-gel transition process is induced by the presence of monovalent
or divalent ions, such as Na+ and Ca2+. Other parameters can also influence the phase transition,
including the polysaccharide concentration, the temperature, and the nature and concentration of
cations. The exceptional rheological properties of gellan gum, such as its thixotropy, pseudoplasticity,
and thermoplasticity [75,76], are further advantages that favor its use in ophthalmology. Notably,
the fluidity of the solution can be increased simply by shaking or slightly warming the preparation,
and the gelation increases in proportion to the concentration of monovalent or divalent cations in the
lacrimal fluid. In vitro experiments have demonstrated a greater effectiveness of divalent cations than
of monovalent ions in promoting the sol-gel transition. In any case, the in vivo tear conditions (i.e.,
the concentration of sodium in tears) are sufficient to induce the gelation process. Eye drops containing
gellan gum and timolol have received market authorization (Timoptic XE) [77].
Carrageenans, a group of water-soluble sulfated galactans extracted from red seaweed,
show similar features to gellan gum in terms of their rheology, gelling properties [78,79], and biological
safety. This suggests that these polysaccharides could also be interesting polymers that could
prolong the residence time of topical ocular formulations [79]. Some authors have suggested that
these compounds, because they are strong polyelectrolytes, may have the same underlying gelling
mechanism as gellan gum.
ALG is another anionic polysaccharide that undergoes gelation via interactions with divalent
cations and with oppositely charged polymers. Some ALG forms are rich in guluronic acid residues and
exhibit a reversible liquid–gel transition after administration. These forms were efficient at reducing
intraocular pressure when used as a vehicle to deliver pilocarpine [80,81]. ALG-pectin combinations
and thiolated pectins have also been studied. The thiolation of pectin increased gelling behavior,
viscosity, and bioadhesive strength, while a combination [82] of pectin and ALG demonstrated good
in vitro release characteristics [83]. Microparticles of ALG and chitosan have been prepared and
used for the loading of 5-fluorouracil [84]. This microparticle formulation increased the delivery of
5-fluorouracil to the aqueous humor in animal experiments. The enhanced delivery was probably a
result of the greater mucoadhesiveness of the chitosan-coated particles as compared to a 5-fluoruracil
solution or the uncoated particles. The optimized formulation was non-irritating and well tolerated
when tested in rabbit eyes.
3.4.3. In-Situ-Forming Gels Influenced by Temperature
Temperature responsiveness is a useful trigger for in-situ formation of drug delivery gels. In this
case, the formulation is in the sol phase at room temperature (20–25 ◦C), and it solidifies in response to
the temperature increase when the polymer is administered to the body (temperature 32–37 ◦C) [85].
Poloxamers are a major example of materials that undergo thermosensitive gelation.
These polymers consist of a central hydrophobic segment (polyoxypropylene) surrounded by a
hydrophilic part (polyethylene oxide). At concentrations above 20% (w/w), poloxamers exhibit reverse
thermal gelation, but this response can be modulated by the addition of cellulosic derivatives, such as
methylcellulose or HPMC, to the formulation [86,87]. The mucomimetic property of poloxamers is
supposedly a result of their hydrophobic and hydrophilic sequences, which simulate mucin action by
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adsorption to the aqueous layer of tears on the hydrophobic epithelium. Since the sol-gel transition
takes place as the temperature increases, accidental gelation during conservation may occur. Owing to
their protective and mucomimetic action, poloxamers have been evaluated for the treatment of dry eye
and as ocular drug delivery systems [88].
The semi-interpenetrating hydrogels of polyhydroxyethyl methacrylate and methylcellulose are
also thermosensitive. An increase in the methylcellulose content increases the viscous component and
provides a better moisture retention capacity of the methylcellulose-containing hydrogels, making
them suitable for ophthalmic applications [89].
3.4.4. In-Situ-Forming Gels Influenced by pH
All pH-sensitive polymers contain pendant acidic or basic groups that can either accept or release
protons in response to changes in environmental pH. This response results in changes in the charge state
of the polymer chains, thereby inducing conformational swelling or shrinking. Polymeric hydrogels
with weakly acidic groups may swell if the external pH increases, while polymers with weakly basic
groups may shrink under the same conditions [90]. The pH-sensitive hydrogels contain polymer chain
networks that are crosslinked to each other and surrounded by a salt solution. A change in the solution
pH will initiate gel swelling or deswelling. This physical process, in general, is not instantaneous,
and modeling the gel swelling/deswelling rate provides a thorough understanding of the gel dynamics.
This knowledge is important when hydrogels are used for controlled drug delivery, as the drug
may release prematurely during the swelling process. These pH-sensitive systems typically exist as
low-viscosity aqueous dispersions, but they undergo spontaneous coagulation in the conjunctival
cul-de-sac in response to an increase in the local pH. One example of this is a chitosan/carbopol mixture
that is liquid at pH 6.0, but it undergoes gelation in the lacrimal fluid pH of 7.4. This system has been
evaluated for the delivery of timolol [91] and ketorolac tromethamine [92].
Recall, however, that the volume of tear fluid is only 7 µL and that tear fluid is only weakly
buffered. Therefore, the pH change may occur in the tear fluid, rather than in the formulation, after the
instillation of a pH-sensitive hydrogel.
3.5. Inserts and Contact Lenses
Ocular inserts were first used in the UK in the early 20th century as local anesthetic eye products.
These gelatin-based inserts were placed under the eyelid to release cocaine. Later, in the 1960s, soluble
ocular drug inserts were introduced for clinical use in the Soviet Union for the delivery of several
ocular drugs, such as pilocarpine. Ocusert was introduced for pilocarpine delivery during 1970s
by the ALZA Corporation (Palo Alto, CA, USA). This topically inserted device released pilocarpine
for a week. In all these cases, increased ocular absorption and prolonged duration of action was
achieved, but these products are no longer used clinically. Difficulties in their clinical use, poor ocular
retention, and reduced patient compliance resulted in the withdrawal of these products from the
commercial market.
Ophthalmic inserts are defined as preparations with a solid or semisolid consistency, whose size
and shape are specially designed for insertion into the eye [77]. These inserts are placed topically
in the lower fornix and, less frequently, in the upper fornix or on the cornea. The initial discomfort
upon administration is a disadvantage that arises from their solid state; other disadvantages include
possible movement around the eye, occasional inadvertent loss during sleep or while rubbing the eyes,
interference with vision, and generally difficult placement (and removal, for insoluble devices) [93,94].
Ocusert is a delicate, insoluble, and non-degradable reservoir device that is filled with sufficient
pilocarpine for 1 week of use, whereas Lacrisert is a soluble mini rod of nonmedicated hydroxypropyl
cellulose that dissolves within 24 h for the treatment of dry-eye syndromes [95]. Ophthalmic inserts
are generally classified according to their solubility behavior and their possible biodegradability.
In general, prolonged drug duration can be achieved with these types of inserts.
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Soluble inserts will dissolve in the tear fluid after instillation. In this case, lacrimal fluid may
penetrate rapidly into the device [96], resulting in fast drug release but potentially blurred vision.
Conversely, the glassy constitution of the insert may increase the risk of insert expulsion from the eye.
Ophthalmic inserts containing cellulose-based polymers are extensively described in the literature [82].
Ethylcellulose, a hydrophobic polymer, can be incorporated into the formulation to decrease insert
deformation and blurred vision [97], but these insoluble inserts must be removed from the eye after
drug release. Film forming properties and biocompatibility of cellulose ethers makes them a good
excipient for modifying ocular insert properties. The addition of methylcellulose to polyacrylic acid
films provided prolonged riboflavin release due to the formation of a hydrogen bond network and a
decrease in irritation effects [98]. Abilova et al. [99] prepared films based on chitosan and its blends with
poly(2-ethyl-2-oxazoline). These films were mucoadhesive, biocompatible, and capable of providing a
sustained drug release when administered topically on the cornea.
Lacrimal fluid contains bicarbonates for buffering the pH to about 7.4, but the capacity of this buffer
system is quite limited. Therefore, in vitro release tests from ionizable polymer inserts should be carried
out using dilute buffers (e.g., 2 mM) [41], as release tests using regular strength phosphate buffers
will result in poor in vivo extrapolation [41]. Insoluble inserts can be classified into two categories:
reservoir and matrix systems. Reservoir inserts consist of a central reservoir of drug enclosed in a
specially designed semipermeable or microporous membrane, which allows the drug to diffuse from
the reservoir at a predetermined zero-order release rate (e.g., Ocusert). Reservoir-controlled release
systems may be manufactured in a wide range of geometries, including conventional tablets/pellets,
laminated films, and other defined shapes (e.g., hemispheres, cylinders, or rods) using, for example,
ALG [100–102] and cellulose as polymeric materials [103].
Contact lenses with presoaked drugs have been tested for ocular drug delivery since the
1970s. Soft hydrophilic contact lenses were developed for prolonged release of several drugs,
such as pilocarpine, chloramphenicol, tetracycline, and prednisolone sodium phosphate [82].
The polysaccharides used in contact lenses include HA and cellulose derivatives [104].
HA is used as a solution for topical artificial tears, and it has proven efficacy in the treatment
of dry eye syndrome. Using molecular imprinting strategies, the delayed release of high molecular
HA from a daily disposable lens can be achieved at a therapeutic rate of approximately 6 µg/h for
24 h [105]. Similarly, the extended release of 120 kDa HPMC at the rate of 16 µg per day [106] has
been reported for the prevention of contact-lens-induced DED. The main drawbacks of using contact
lenses as therapeutic materials are their high cost of manufacture and their low drug-loading capacity,
which is not sufficient to build up a therapeutic concentration in the eye for most drugs [104]. Contact
lenses are also changed frequently, and drug loading should be done professionally, not by the patient
at home. Furthermore, drug release from the contact lenses to the storage liquid must be avoided.
For these reasons, no drug-containing contact lenses have been launched as clinical products.
3.6. Dispersed Systems
Dispersed systems based on liposomes, nanoparticles, or nanocapsules have been extensively
studied for ophthalmic drug delivery, but the development of marketable dispersed products has been
challenging. The major issues for this type of delivery system include problems in the percentage of
dispersed phase/entrapment coefficient (i.e., how much of the active ingredient can be embedded to the
dispersed phase), the stability and shelf life of the product, difficulties in antimicrobial preservation,
tolerance of the used surfactants, and, last but not least, the complexity of large-scale manufacture
of sterile preparations. A recent publication illustrating the importance of drug loading in topical
ocular products showed that the required loading levels are strongly dependent on the drug potency
and the desired duration of action [107]. In addition to adequate drug loading, the retention of the
administered particles in the conjunctival pouch must also be of sufficient duration to allow drug
release from the particles before they are drained away from the precorneal area [82]. Storage of the
dispersed system in liquid form imposes additional problems, since the drug will be equilibrated and
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released to the aqueous storage medium. Freeze-drying is also not an appealing option for topical eye
drops, because each eye drop would require reconstitution from the powder form before its instillation
into the eye.
Figure 2 shows the different types of dispersed systems used in ophthalmology for loading with
active compounds; their special features are discussed below.Pharmaceutics 2020, 12, 22 11 of 29 
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with chitosan coated solid lipid nanoparticles. HA has also been used as a coating for lipid-based 
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3.6.1. Liposomes
Liposomes (Figure 2d) are microscopic vesicles composed of alternating aqueous compartments
and lipid bilayers (mainly phospholipids and cholesterol). The efficacy of liposome use in topical
ophthalmic therapy depends on several parameters, including (1) the drug encapsulation efficiency,
(2) the size and the surface charge of the vesicles, (3) the distribution of the drug in the liposomes, (4) the
stability of the liposomes after instillation, (5) the residence time of the liposomes in the conjunctival sac,
and (6) the affinity of the liposomes for the corneal surface [82]. Liposomes and other colloidal drug
carriers offer some potential for ocular drug delivery, since they can be used for sustained drug release
and prolonged ocular retention. However, liposomes will drain rapidly from the ocular surface if they
do not adhere onto the corneal surface. Insufficient residence time of liposomes in the ocular cavity
leads to a reduced drug bioavailability, because most liposome-associated drug would be drained
away from the eye before its release. Corneal adhesion can be enhanced in different ways, including
the use of (1) ganglioside-containing liposomes together with wheat germ agglutinin, a lectin that
binds to both the cornea and gangliosides, (2) liposomes coated with antibodies to components in the
corneal surface, and (3) liposomes coated with mucoadhesive polymers.
Polysaccharides have been used to enhance the properties of ocular liposomes. Chitosan enhances
the transcorneal permeability of drugs by disrupting the tight junctions in epithelial cellular sheets [27].
Coating of timolol-loaded liposomes with chitosan increased the apparent permeability coefficient
of timolol by 2–3-fold when compared to timolol in solution and in uncoated liposomes. The drug
retention time in the precorneal area was also increased by the mucoadhesive properties of chitosan [108].
Balguri et al. [109] also reported that ocular delivery of indomethacin was improved with chitosan
coated solid lipid nanoparticles. HA has also been used as a coating for lipid-based formulations.
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This approach increased mucoadhesion of niosomes (non-ionic surfactant-based vesicles) and the
ocular bioavailability of the loaded drug tacrolimus [110].
3.6.2. Micro- and Nanoparticles
Micro- or nanoparticles are divided into two groups: micro- or nanospheres and micro- or
nanocapsules. Microspheres are monolithic particles consisting of a porous or solid polymer matrix
(Figure 2a,b), whereas microcapsules consist of a polymeric membrane surrounding a solid or a liquid
drug reservoir (Figure 2c,d) [111]. In practice, the term nanoparticle (or microparticle) is applied
both to nanospheres/microspheres and nanocapsules/microcapsules, because the distinction between
real capsule structures or matrix-type particles is difficult. The active compound can be dispersed or
dissolved in the inner polymer matrix, but it can also be dissolved in the inner reservoir of micelles
(Figure 2e), trapped within the particle structure (by gelation, as in Figure 2g, or a layer-by-layer
technique, as in Figure 2c), or conjugated to the polymer by forming self-assembling particles (as in the
case of hydrophobic drugs).
Nanocapsules can be used to increase drug absorption from the ocular surface. The aim
with these preparations is to increase corneal penetration and prolong the therapeutic response.
Corneal penetration of indomethacin was increased 4–5-fold across isolated rabbit corneas when
nanocapsules were used as drug carriers [112]. Coating of polycaprolactone-based indomethacin
nanocapsules with chitosan, poly(l-lysine), or both, converted the nanocapsules to cationic
mucoadhesive formulations [112]. The chitosan-coated nanocapsules enhanced the corneal penetration
of indomethacin and showed good ocular tolerance.
Similar promising findings were also reported for celecoxib-loaded cationic chitosan or anionic
ALG nanoparticles, which showed sustained drug release without a burst effect; the release followed
a Higuchi non-Fickian diffusion mechanism. These particles were also non-toxic in cell tests [113].
Other reports have investigated the ocular delivery of piroxicam (a non-steroidal anti-inflammatory
drug) in pectin microspheres [114]. This system increased ocular drug bioavailability and was
well tolerated.
Yuan et al. [115] prepared self-assembled nanoparticles based on a succinyl-cholesterol derivative
of chitosan and used them for topical administration of cyclosporine A. However, isotope label
tracking experiments did not reveal significant trans-corneal drug permeation. De Campos et al. [116]
encapsulated cyclosporine A in chitosan nanoparticles by ionotropic gelation. In vivo administration
resulted in therapeutic drug concentrations in the cornea and conjunctiva.
Gene therapy is another promising tool for the topical treatment of ocular diseases. Toropainen
et al. [117] showed that transfection of corneal epithelial cells can result in the delivery of a secreted
transgene product (in this case, secreted alkaline phosphatase) to the anterior chamber. This work
demonstrated that topical gene delivery might be used for the treatment of ocular surface layers and
anterior chamber tissues. For example, chitosan can be used for DNA binding and condensation.
Chitosan’s positive surface charges can prolong the retention of the formulation onto the negatively
charged ocular surface. HA can be used to decrease the cationic charge of DNA polyplexes, and it
may facilitate CD44-mediated endocytosis into the cells. De la Fuente et al. [118] investigated in vivo
plasmid DNA (pDNA) delivery to the corneal and conjunctival epithelia to find that positively charged
HA–chitosan/pDNA polyplexes provided efficient transfection by a CD44-mediated mechanism.
3.6.3. Inclusion Complexes (Clathrates)
Typically, cyclodextrin-based formulations are used to formulate sparingly soluble drugs, such as
carbonic anhydrase inhibitors (for glaucoma) [119] or corticosteroids (for treating inflammation) [120].
However, the action of these formulations might be equivocal in some cases. For example, the use of a
cyclodextrin solution of dorzolamide hydrochloride in rabbits resulted in intraocular levels lower than
those achieved with the corresponding suspension. On the contrary, promising results were reported
for acetazolamide in hydroxypropyl-β-cyclodextrin formulations, as these improved the intraocular
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pressure [121]. The use of as low a concentration as possible for drug complexation is critical, because
the drug must be effectively released from cyclodextrin since these complexes do not permeate into
the eye [122]. Too high a cyclodextrin concentration will limit drug release and ocular bioavailability.
The best ocular drug absorption can be obtained if a low cyclodextrin concentration (to increase drug
solubility) is combined with increased eye drop viscosity (with a polymer solution to increase retention
on ocular surface), as shown in vivo with pilocarpine prodrugs [123,124].
In some cases, cyclodextrins enable the formulation of otherwise extremely poorly soluble
drugs, such as endogenous cannabinoids (e.g., anandamide) and derivatives that reduce intraocular
pressure [125].
Recently, dexamethasone was formulated in cyclodextrin containing eye drop solutions and
compared with dexamethasone suspensions [126]. The hydroxypropyl cyclodextrin formulation
showed increased dexamethasone solubility by orders of magnitude and resulted in substantial
increases in ocular drug absorption, even in the posterior eye segment.
3.7. Summary
Several studies have shown that improvements in topical ocular drug delivery can be achieved
with polysaccharide vehicles. Gel forming systems, inclusion complexes of drugs, and nanocomplexes
for transfection of gene medicines are particularly promising approaches that are enabling the ocular
delivery of difficult compounds. Note, however, that systemic absorption from the ocular surface sets
the maximal ocular bioavailability at approximately 10%. Drainage of the formulation and incomplete
drug release onto the ocular surface cause further significant reductions in ocular bioavailability,
and these factors remain to be optimized. Furthermore, drug release during storage prior to use is a
serious limitation in the case of disperse formulations and contact lens-based drug delivery systems.
4. Intravitreal Administration
The effective treatment of ocular pathologies requires that therapeutic drug concentrations be
achieved and maintained in the target tissues, such as the retina in the posterior segment. Intravitreal
injection is an effective means of drug delivery to the posterior segment, but it is an invasive mode of
delivery. Currently, more than 22 million intravitreal anti-vascular endothelial growth factor (VEGF)
drug injections are given annually worldwide [127]. Even though intravitreal injections are generally
safe, the monthly and bimonthly requirements for these injections in long-term treatment may cause
problems such as infection and reduced patient compliance [128–132]. For these reasons, intravitreal
drug delivery systems are needed that will maintain therapeutic drug concentrations for an extended
time, prolong the drug effect, and reduce the required number of applications [128,130,131,133–135].
Obviously, the systems must also be safe and ideally they must be biodegradable, as biodegradable
drug delivery systems do not require subsequent surgery to remove them from the eye [133].
One of the strategies for long-acting intravitreal drug delivery is to use polymers for extended
drug release [130,136]. Intravitreal drug administration requires control of system parameters, such as
the size, surface charge, lipophilicity, and shape of drug carriers [137–141], as these parameters affect
drug release and retention of the delivery system within the vitreal cavity. The retention of the delivery
system and its components within the vitreal cavity depend, in turn, on the physical barriers between
the eye and blood circulation and the chemical composition of the vitreous humor [133,141–147].
The main factors defining the elimination of drug delivery materials from the vitreous humour include:
(1) the vitreous humor, (2) the inner limiting membrane (ILM), (3) the blood-retina barrier (including
the RPE and blood vessel walls in the retina and ciliary body), and (4) the degradation rate of polymer
materials in the vitreous humor [147]. Polymers in the vitreous can be eliminated via the anterior
pathway by diffusion from the vitreous into the aqueous humor and then outflow from the eye [148].
Alternatively, the polymers might be eliminated posteriorly, through the vitreous humour, the ILM,
and the blood retina barriers, although permeation through this pathway is limited by molecular
size [148]. Therefore, particles or polymers are unlikely to escape posteriorly from the vitreous unless
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they are first degraded into smaller fragments within the vitreous humor [148]. Small molecular weight
drugs are mostly eliminated via the posterior route because they are able to permeate through the ILM
and blood retina barrier [149].
The vitreous humor has a volume of 4 mL in the human eye [137], and it consists of a negatively
charged 3D matrix based on collagen and HA [2,137,143]. The mobility of large particles is hindered due
to steric effects, because the limiting mesh size of the vitreous is 550 nm [137,144,150,151]. Large drug
molecules diffuse through the vitreous humor slightly slower than small molecules do [2], but the
differences in diffusion rate among particles are much greater. The particle surface charge is a more
important factor than the particle size in determining the vitreal particle diffusion rate [137,152].
Negatively charged and neutral particles move freely in the vitreous humor, whereas the mobility of
positively charged particles is severely limited by the interactions with the anionic components of the
vitreous gel [141]. Therefore, hydrophilic, negatively charged or uncharged particles should be used
for intravitreal drug delivery [137,147,151,153,154].
HA and collagens are the main components in the vitreous humor, which also contains also a
minor quantity of sulfated glycosaminoglycans (chondroitin sulfate and heparan sulfate) [137,143].
The concentration of HA in the vitreous gel is 65–400 µg/mL, and its MW is 2–4 MDa [143]. Vitreous
humor collagens (300 µg/mL) are represented by the heterotypic collagen fibrils of Type II, Type V/XI,
and Type IX collagens [137,143]. Other structural proteins, such as fibrillin and collagen-binding
macromolecules (opticin and VIT1), are also present in small quantities in the vitreous gel [143].
The ILM is an anatomical barrier between the vitreous and the neural retina [141,147,151,155].
It consists of laminin, proteoglycans, and collagen (Type IV), and it limits the access of drug delivery
systems and macromolecules to the retina after intravitreal injection [141,147].
The RPE is an epithelial membrane with tight inter-cellular junctions [148] and is located between
the neural retina and choroidal blood circulation. The RPE nearly completely blocks the transfer of
macromolecules from the retina into the blood circulation [156].
4.1. Hydrogels
Hydrogels are polymeric depots that physically hold drug molecules to allow controlled drug
release [4,136,142,146,157]. Polysaccharides (e.g., HA, ALG, chitosan, and its derivatives) have been
used to fabricate hydrogels for intravitreal drug delivery [146]. The hydrogel network is formed
by crosslinking macromolecules through chemical (covalent) bonds and/or physical interactions
(hydrophobic associations, electrostatic interactions) [146,158]. The resulting hydrogel matrices
generate physical or chemical barriers that limit the diffusion of drug molecules, thereby providing the
basis for controlled drug release. Drug release mechanisms from hydrogels include diffusion, swelling,
degradation, or combinations thereof [146].
Yu et al. [159] used the effective properties of HA (MW 29 kDa) to develop a HA/dextran-based
in-situ hydrogel for intravitreal bevacizumab delivery. The HA was chosen as a non-toxic and
endogenous ocular polymer. The delivery system was able to maintain a therapeutic concentration of
bevacizumab for six months, and the concentration of bevacizumab 6 months after the gel injection
was about 107 times higher than the concentration obtained after a bolus intravitreal injection. Clearly,
HA based hydrogel formulation has the potential for prolonged dosing intervals of bevacizumab in
the treatment of neovascular age-related macular degeneration.
4.2. Dispersed Systems
4.2.1. Micro and Nanoparticles
Dispersed microparticles and nanoparticles have been tested for intravitreal drug delivery.
There are two main aims for this approach: (1) prolonged drug retention and release in the vitreal
cavity, and (2) improved drug delivery to the retinal and choroidal targets.
Pharmaceutics 2020, 12, 22 15 of 30
Microparticles improve the drug retention in the vitreous [160]. Sustained drug release from
microparticles can be realized by drug diffusion from the polymer or degradation of the microparticles.
Accordingly, the time and rate of release can be controlled by the size of the microparticles, the thickness
of their walls, and the nature of the polymers [161].
Elsaid et al. [162] studied ranibizumab delivery using a “system-within-system” of
PLGA-microspheres that contained nanoparticles. The polysaccharide nanoparticles were based
on HA (MW 1500 kDa), chitosan (MW ≤ 400 kDa, degree of deacetylation 80–95%), and chitosan-
N-acetyl-l-cysteine (CNAC). The nanoparticles were generated using an electrostatic binding between
chitosan or CNAC and TPP or HA/TPP. The size of particles was 17–350 nm and their ζ-potentials
varied from −1.4 to +12 mV. The final microparticles (containing nanoparticles) had a slightly positive
ζ-potential (2–9 mV) and a microparticle size of 3.0–6.0µm in diameter. The addition of CNAC increased
the ranibizumab entrapment efficiency up to 69% (vs. 29% in the unmodified PLGA microparticles).
Presumably, ranibizumab was solubilized by the hydrophilic CNAC, based on thiol group-mediated
chemical interactions between N-acetyl-l-cysteine and ranibizumab. The use of CNAC improved the
release profile of ranibizumab from the PLGA microparticles by minimizing the initial burst release.
Wang et al. [161] formulated ALG-based microspheres with retinoic acid as an active
pharmaceutical substance. ALG microspheres 65–115 microns in size were formed by calcium-based
cross-linking. The retinoic acid release was stable, slow, and effective for about one month in
an in vivo study. The retinoic acid release from ALG microparticles was primarily controlled by
microparticle degradation.
Chitosan and HA are the most commonly used polysaccharides for the preparation of nanoparticles
for ophthalmic drug delivery. HA is deemed a particularly excellent choice for drug delivery in the
posterior segment of the eye. HA-based nanoparticles are mobile in the vitreous gel, and they can
reach the retina and choroid [130]. HA has also been used as a coating for other nanoparticle materials.
Huang et al. [144,163] developed a technology for manufacturing HA-coated (MW 120 kDa)
albumin nanoparticles. These nanoparticles were used to deliver Connexin43 mimetic peptide to
prevent secondary damage after ischemic and inflammatory diseases of the retina. These nanoparticles
had a negative ζ-potential (−44 mV) and small mean size (253 nm) that promoted their diffusion from
the vitreous humor to the retina. Coating of the nanoparticles with HA prolonged the drug retention
in the target eye area for up to eight weeks.
Gan et al. [164] designed HA-modified nanoparticles with chitosan and cholesterol.
The nanoparticles were prepared by hydrating a dried lipid cholesterol film with a chitosan solution.
The nanoparticles were then modified with HA using the binding agents EDC and NHS at pH 4.0 The
final HA-modified nanoparticles had mean diameters of 350–450 nm, and their ζ-potential ranged from
−20 to −30 mV. The HA-modified nanoparticles were used to study the cellular uptake via interaction
with CD 44 receptors. HA with a MW of 200–400 kDa improved the cellular uptake of the nanoparticles,
possibly by a CD44-mediated mechanism, whereas HA with a MW of more than 1000 kDa reduced the
cellular delivery of nanoparticles.
Andrei et al. [165] synthesized chitosan–gelatin-based nanoparticles for intravitreal cefuroxime
delivery using a technique involving double crosslinking in a double emulsion. Nanoparticles of low
MW 70 kDa with a deacetylation degree of 91% had a particle size of ≈225 nm and an encapsulation
efficiency of about 47%. A peak characterized the profile of cefuroxime release (pH 7.4) in the first
hour and a subsequent sustained release followed for 48 h. In vivo studies showed that the cefuroxime
released from chitosan–gelatin nanoparticles was eight times more effective than free cefuroxime.
Glycol chitosan nanoparticles (hydrodynamic diameter 174 nm, ζ-potential 9.6 mV) were used
as a matrix for the intravitreal delivery of cerium oxide nanoparticles. Cerium oxide nanoparticles
have strong antioxidant and antiangiogenic properties, but their use is limited by their low water
solubility [166]. Glycol groups can mask the amino groups of glycol chitosan and block the binding to
an anionic vitreous gel [139]. The glycol chitosan nanoparticles significantly increased the aqueous
solubility of cerium oxide and, accordingly, its bioavailability, while also reducing cerium oxide toxicity.
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Intravitreal injections of this type of nanoparticle significantly ameliorated the damage associated with
oxidative stress in mouse eyes [166].
4.2.2. Polyplexes
Polysaccharides are also used to bind and deliver polynucleotides, such as RNA and DNA,
into cells. Cationic polysaccharides (e.g., chitosan) form nanoparticle-sized complexes (i.e., polyplexes)
with anionic polynucleotides.
Positively charged polyplexes are effectively taken up by the cells, but their poor mobility in the
vitreous and ILM limits their cellular delivery [152,153]. However, ocular distribution can be improved
with a HA coating. For example, Lee et al. [167] used HA (MW 5000 Da) to coat multimerized siRNA
(polysiRNA) polyplexes with branched polyethyleneimine. The polysiRNA polyplex had a size of
about 260 nm and a negative ζ-potential of about −5 mV. The polysiRNA polyplex was efficiently
distributed through the vitreous and retina and reached the subretinal space [36], since it did not
interact with the negatively charged components of the vitreous gel. Presumably, the polyplexes
bound to the CD44 receptors on the Müller cells. The polysiRNA polyplexes were non-toxic, and they
maintained pharmacological activity after 1 and 7 days.
Martens et al. [168] used HA of various MWs (22, 137, and 2700 kDa) as an electrostatic coating
for polyplexes of an anionic pDNA with a cationic N,N′-cystamine bisacrylamide-4-aminobutanol
vector to improve their distribution in the vitreous body. The polyplex charge was rendered negative
with a four-fold excess of HA. Polyplexes with low molecular weight HA were mobile in the vitreous
(22 and 137 kDa) and provided maximal gene expression (22 kDa).
4.2.3. Self-Assembling Nanoparticles
Micelles can be obtained from amphoteric macromolecules that self-assemble in aqueous solution
to form a hydrophobic core and a hydrophilic shell. Water-insoluble drug molecules can be incorporated
into the hydrophobic core, while the hydrophilic shell provides stability for the micelles in the aquatic
environment [130,138].
Koo et al. [151] synthesized self-assembling amphiphilic nanoparticles based on four polymers:
polyethyleneimine (MW 25 kDa), glycol chitosan (MW 250 kDa, degree of deacetylation 82.7%),
HA (MW 2.34 MDa), and human serum albumin. The hydrophobic component was 5b-cholanic acid.
The nanoparticle sizes were approximately the same (210–340 nm), but the nanoparticle ζ-potentials
varied from −23 to +33 mV. Strongly positively charged polyethyleneimine nanoparticles interacted
with anionic vitreous components and were poorly distributed. Negatively charged human serum
albumin and HA nanoparticles demonstrated a broad distribution in the vitreous humor and the retina.
Positively charged heterogeneous glycol chitosan and polyethyleneimine/glycol chitosan nanoparticles
penetrated through the vitreous humor, but they did not penetrate through the ILM into the retina.
The free movement of positive heterogeneous particles in an anionic vitreous gel is possibly related to
the anti-fouling effects of glycol groups. This behavior confirmed the correlation between the properties
of the nanoparticle surfaces and intravitreal distributions.
4.3. Conjugates (Covalent Modification)
The diffusional velocity of molecules in a vitreous gel and their clearance from the eye depends
on the molecular size [149]. Thus, the pharmacological effects of intravitreally administered drugs may
be prolonged with increasing molecular size. Covalent conjugation to polymers can therefore be used
to increase the apparent size of drug molecules [136], making the use of large polymer molecules a
rational drug delivery strategy [169,170].
HA has been used to reduce clearance and increase the residence time of drugs in the vitreous
humor [136]. Altiok et al. [170,171] conjugated anti-VEGF drug (soluble VEGF receptor; sFlt-1) to
HA (MW 300 kDa, 650 kDa, and 1 MDa) to provide sustained release and prolonged retention in
the vitreous [170]. The half-lives were about ten times longer for the HA conjugates than for the
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unconjugated sFlt-1. Conjugation of sFlt-1 with HA did not change the pharmacological activity of this
protein drug [170,171]. This study nicely demonstrated the potential use of polymer conjugation in
intravitreal drug delivery. Unfortunately, this approach has been very rarely used thus far.
4.4. Intravitreal Implants
Intravitreal implants are based on biodegradable or non-biodegradable polymer containers loaded
with active pharmaceutical substances. Intravitreal implants are used for controlled release and
prolonged drug action [139,142,157]. Some non-degradable and biodegradable (polylactide- based)
implants are already in clinical use, but these products are not based on polysaccharides [172].
Polysaccharides have been utilized experimentally for controlled release in the vitreous.
For example, Van Kampen et al. [173] manufactured hollow cylinders (1 mm in diameter, 10 mm in
length) of 51 kDa HA that was cross-linked with divinyl sulfone. Diffusional release of proteins from
these implants was based on hydrogel swelling and the density of crosslinking. A low degree of
swelling and a high crosslink density were achieved by optimizing the ratios of HA and the divinyl
sulfone cross-linker. The release of protein from the hollow cylinders was at least 2.5 µg per day for 4.5
months. This system can be used for the delivery of active pharmaceutical ingredients to the retina for
the treatment of retinal pathologies.
Some implant designs involve inclusion of drug-loaded nanoparticles in the implant. For example,
an ophthalmic implant of zinc-cross-linked HA with bevacizumab-loaded chitosan nanoparticles was
fabricated for the treatment of choroidal neovascularization [174]. The bevacizumab-loaded chitosan
(50 kDa) nanoparticles were prepared by ionic gelation. The mean size of the nanoparticles was 78 nm,
the encapsulation efficiency was 68%, and the loading efficiency was 16%. The in vitro release results
showed a prolonged release of bevacizumab from the polymer matrix for two months. However,
the role of the nanoparticles is not clear in this context, because bevacizumab acts in the extracellular
space, so improved intracellular delivery is not needed. The prolonged release of protein drugs can
also be achieved without nanoparticles.
Manna et al. [155] used chitosan (MW 50–190 kDa and degree of deacetylation > 75%) as
a hydrophilic, non-toxic, biodegradable polymer to obtain intravitreal polymer matrices with
methotrexate. The chitosan was biodegraded by hydrolytic enzymes to produce amino sugars,
which were quickly metabolized. The resulting chitosan matrices were coated with hydrophobic PLA
to prolong the release of methotrexate. The implant released methotrexate at the rate of 0.2–2.0 µg/day
for more than 50 days.
5. Periocular Administration
5.1. Subconjunctival Delivery
The subconjunctival space is a widely used route for injections, but regular drug solution injections
have a short duration of action. However, the subconjunctival space can also be used for sustained
drug release. Drug clearance from the subconjunctival space depends on the molecular size, as small
molecules are rapidly lost to the conjunctival systemic circulation, whereas macromolecules are retained
longer in the sub-conjunctival space [175]. Particles can be retained for much longer durations in the
subconjunctival space than can dissolved molecules; for example, particles larger than 200 nm can be
retained for more than 60 days [176].
Ocular drug permeation from the subconjunctival space takes place across the sclera, which is
permeable even to polymers. Interestingly, polysaccharides of the same hydrodynamic radius as an
antibody have higher permeability coefficients, probably due to their flexible structures. The effective
pore size of the sclera has been estimated at approximately 16 nm [177]. After scleral permeation,
the compounds reach the ciliary body anteriorly and the choroid posteriorly. For retinal delivery,
a periocularly administered drug should also be able to permeate across the RPE, which forms a tight
cellular barrier due to tight junctions between the RPE cells [175].
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For injectable ocular formulations, slow release of up to several weeks or months is preferable
to avoid the need for frequent injections. Crosslinked polymeric systems (inserts, particles) may
provide suitable release profiles. A formulation of HA crosslinked with isocyanate-functionalized
1,2-ethylene glycol bis(dilactic acid) was generated and loaded with latanoprost. After subconjunctival
administration, latanoprost release was extended for up to 160 days, but complete biodegradation of
the material required an additional four months [178].
In-situ gelling systems are a promising class of subconjunctival injectables, as they are liquid at the
moment of injection and form a gel in the subconjunctival area, thereby forming a depot for prolonged
release of drugs. Several gelling system strategies have been used. For example, Zarembinski et al. [179]
developed a hydrogel based on glutathione-modified carboxymethyl HA. Gelation was based on a
thiol-disulfide exchange reaction. Gelation occurred within 5 min, resulting in a soft gel that could be
used to deliver different cargos, including drugs, proteins, and cells.
Physically crosslinked hydrogels can also be used as formulations for prolonged drug
release. Cheng et al. [180] developed a thermoreversible hydrogel based on chitosan, gelatin,
and β-glycerophosphate. A latanoprost-loaded hydrogel was formed at body temperature within
1 min. A single subconjunctival injection provided a significant decrease in the intraocular pressure
(IOP) within 8 days, and the effect lasted for up to 28 days. In this case, the long delay before the
pressure-decreasing effect could prove problematic in a clinical setting.
Sustained drug delivery is usually used to treat chronic diseases, but it is also valuable
as post-surgical therapy. For example, glaucoma filtration surgery requires modulation of the
wound-healing process. A carboxymethyl chitosan hydrogel loaded with 5-fluorouracil and
bevacizumab, and then in-situ crosslinked with genipin, was injected subconjunctivally to limit
scar formation and vascularization of the wound. The hydrogel was nontoxic to the scleral tissue and
effectively delayed scar formation [181].
Shear-reversible gels do not utilize cross-linking, but they can be injected directly in the gel state
because they undergo thinning in response to injection shear. A gel based on carboxymethyl hexanoyl
chitosan was capable of forming a dispersion of self-assembled colloids within the gel [182]. Overall,
drug release was controlled by the release from the particles and not by diffusion of the dissolved drug
in the gel. A single administration of latanoprost-loaded gel lowered the IOP for up to 40 days.
Methylcellulose and ι-carrageenan dispersions have been evaluated as systems for transscleral
delivery of macromolecules [183]. Periocular injection of a gel loaded with antisense oligonucleotides
against a junction protein (Cx43) led to a significant increase in the bioavailability in the sclera and
choroid when compared with an injection of an oligonucleotide solution. However, in vitro studies did
not reveal any enhancement in scleral permeability. Therefore, the positive in vivo result is explained
by prolonged drug retention at the site of administration.
Wu et al. [184] studied the tolerability for subconjunctival injections of a mucoadhesive
polysaccharide isolated from Bletilla striata. This mucoadhesive is a high-MW, nonionic, neutral,
and branched polysaccharide that consists of α-mannose and β-glucose monomers. Subconjunctival
injection of 10 mg/mL B. striata polysaccharide did not cause pathological changes or an inflammatory
response, but at higher concentrations (40 or 80 mg/mL), a slight and transient inflammatory response
was seen in rabbit eyes. B. striata polysaccharide did not cause lesions in the ocular tissues.
Rong et al. [185] prepared an injectable drug delivery system by combining a PLGA-PEG-PLGA
hydrogel with insulin-loaded chitosan nanoparticles. Insulin was loaded into the chitosan nanoparticles
by ionotropic gelation with TPP. The gel-nanoparticle combination was injected subconjunctivally
into rat eyes. The insulin release time was more than 60 days, which was markedly longer than the
release periods obtained with the chitosan-based nanoparticles or the PLGA-PEG-PLGA hydrogel
alone. Subconjunctival injection of the system did not cause any undesired side effects, including
damage to the retinal function, structural changes, cell death in the retina, or glial cell activation.
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5.2. Suprachoroidal Delivery
Suprachoroidal injection with microneedles is a relatively new and still experimental mode of
periocular drug administration [169]. Suprachoroidal injections are made between the sclera and
choroid, thereby avoiding the scleral penetration barrier and sub-conjunctival drug loss to the blood
circulation [148]. Retinal bioavailability after suprachoroidal injection is less than that seen after
intravitreal injection but higher than after sub-conjunctival delivery [175]. Suprachoroidal injection of
a simple drug solution results in rapid drug elimination to the blood circulation, but polymers can be
used to prolong the drug retention at the injection site.
Saline injection results in solution spread over one third of the suprachoroidal space, because this
compartment is very thin and limited in space. Addition of a polymer prolongs the retention in the
suprachoroidal space and helps to control the solution spread. Rheological properties of the polymer
are important in this regard: high MW and moderately non-Newtonian polymeric solutions (e.g., HA)
enhance particle spreading, whereas strongly non-Newtonian polymer solutions (e.g., methylcellulose,
CMC) are immobilized at the injection site. For example, an injected solution of Discovisc (1.6 MDa
HA) is eliminated in one week, while 700 kDa CMC is retained at injection site for 3 weeks [186].
Jung et al. [187] investigated the possibility of targeting formulations to the posterior part of the
eye by suprachoroidal space injections of non-mixed particles with HA hydrogel in a single injection.
After injection, swelling of the hydrogel pushes the particle suspension to the back of the eye (toward
the macula and optic nerve). This approach allowed targeted delivery of 76% of the injected 2-µm
particles to the posterior part of the suprachoroidal space.
6. Subretinal Delivery
Subretinal injections are made between the RPE and the neural retina, making this a technically
demanding mode of drug administration. Subretinal delivery avoids the barrier of the RPE, as the
drug is placed in the immediate vicinity of the neural retina. For example, chitosan microparticles have
been used for sustained protein delivery to the suprachoroidal space [172]. Protein was encapsulated
into the particles with ionotropic gelation, and the chitosan microparticles showed long-term protein
delivery to the retina. However, clustering of the cationic particles induced cytotoxicity at high
concentrations [188].
Cationic polymers, such as chitosan and its derivatives, have been widely investigated as gene
delivery systems because the polycationic nature of cationic polymers support the condensation of
nucleic acids (e.g., DNA, RNA). Sub-retinal injections are the most effective way to administer genetic
therapies to the retina. However, limited polyplex diffusion in the vitreous humor and the ILM barrier
hamper the efficacy of intravitreal delivery of nucleic acids.
Mitra et al. [189] used glycol chitosan (MW 250 kDa) for pDNA delivery. Glycol chitosan
completely bound pDNA at a 25:1 mass ratio (glycol chitosan/pDNA) and formed ellipsoidal particles
with 250 nm hydrodynamic radius and ζ-potential of 25 mV. At 14 days after subretinal injection,
the expression of the transgene (green fluorescent protein, in this case) was seen in the RPE cells,
while neuronal cells in the retina were not transfected. No retinal toxicity was seen in this experiment.
Oligochitosans (MW 7.3 kDa) were also used for subretinal injections of DNA encoding green
fluorescent protein [174]. Although no significant transfection was observed in cultured ARPE-19
cells at N/P ratios of 10–30, transfection of the retinal pigment epithelium and the outer segment of
photoreceptors was evident after sub-retinal injection at an N/P ratio of 10. [190]. Oligochitosan (5 kDa)
has also been used for siRNA delivery into the RPE [191]. Subretinal injections of polyplexes (N/P 50:1)
induced target gene knockdown in a dose-dependent manner in autoimmune uveitis model.
7. Future Aspects
Polysaccharides clearly have beneficial properties that can facilitate ocular drug delivery,
cell therapy, and tissue engineering. Numerous reports have described recent advances, but some
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concerns and poorly explored aspects remain. For example, biodegradation of polysaccharides in
the in vivo situation is difficult to evaluate, and the expression of most degradative enzymes has
not been characterized in ocular tissues. Therefore, information about polymer degradation and the
rationale for polymer design are not yet optimal. Polymer degradation may influence material removal
from the eye [148], and a slower polymer degradation than the rate of drug release may result in
empty and unnecessary polymer “ghosts” that will stay in the eye for too long a duration. Therefore,
synchronizing the polymer degradation and elimination with the duration of drug release and cell
differentiation is of utmost importance. Unfortunately, the design of these systems is hampered by a
lack of necessary background information.
The safety of ocular biomaterials is critically important for the development of drug delivery
and tissue engineering materials. Many publications have reported biocompatibility and a lack of
toxicity, but these conclusions must be treated with some caution. Typically, toxicity tests involve
simple in vitro cell toxicity assays (viability, proliferation, or inflammation), but the situation in the
living eye is more complicated. Many subtle mechanisms of toxicity may cause problems during
extended treatments. Therefore, detailed and long-term immunological, biochemical, morphological,
and functional tests are needed before these materials can be accepted for clinical use.
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Abbreviations
ALG alginic acid or sodium alginate
CMC carboxymethyl cellulose or sodium carboxymethyl cellulose
CNAC chitosan-N-acetyl-l-cysteine
DED dry eye disease
HA hyaluronic acid or sodium hyaluronate
hESCs human embryonic stem cells
hiPSCs human induced pluripotent stem cells
HPMC hydroxypropyl methylcellulose
HUVECs human umbilical vein endothelial cells
ILM inner limiting membrane
IOP intraocular pressure
MW molecular weight
pDNA plasmid DNA
PEG polyethylene glycol
PLGA poly(lactic-co-glycolic acid)
PNIPAAm poly(N-isopropylacrylamide)
polysiRNA multimerized small interfering RNA
RGD adhesion peptide (Arg-Gly-Asp)
RPE retinal pigment epithelial cells
RPCs retinal progenitor cells
TPP sodium tripolyphosphate
TSP tamarind seed polysaccharides
VEGF vascular endothelial growth factor
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